Pieris Pharmaceuticals Statistics
Share Statistics
Pieris Pharmaceuticals has 1.32M shares outstanding. The number of shares has increased by -98.66% in one year.
| Shares Outstanding | 1.32M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 1.30M |
| Failed to Deliver (FTD) Shares | 107 |
| FTD / Avg. Volume | 0.54% |
Short Selling Information
The latest short interest is 22.50K, so 1.7% of the outstanding shares have been sold short.
| Short Interest | 22.50K |
| Short % of Shares Out | 1.7% |
| Short % of Float | 1.73% |
| Short Ratio (days to cover) | 3.52 |
Valuation Ratios
The PE ratio is -0.67 and the forward PE ratio is -80.6.
| PE Ratio | -0.67 |
| Forward PE | -80.6 |
| PS Ratio | 0.38 |
| Forward PS | 2.5 |
| PB Ratio | 0.61 |
| P/FCF Ratio | -0.3 |
| PEG Ratio | n/a |
Enterprise Valuation
Pieris Pharmaceuticals Inc. has an Enterprise Value (EV) of -1.00M.
| EV / Earnings | 0.04 |
| EV / Sales | -0.02 |
| EV / EBITDA | 0.04 |
| EV / EBIT | 0.03 |
| EV / FCF | 0.02 |
Financial Position
The company has a current ratio of 3.24, with a Debt / Equity ratio of 0.
| Current Ratio | 3.24 |
| Quick Ratio | 3.24 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.92% and return on capital (ROIC) is -111.2%.
| Return on Equity (ROE) | -0.92% |
| Return on Assets (ROA) | -0.63% |
| Return on Capital (ROIC) | -111.2% |
| Revenue Per Employee | 930.65K |
| Profits Per Employee | -533.54K |
| Employee Count | 46 |
| Asset Turnover | 1.11 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 0.38% in the last 52 weeks. The beta is 0.66, so Pieris Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 0.66 |
| 52-Week Price Change | 0.38% |
| 50-Day Moving Average | 16.45 |
| 200-Day Moving Average | 14.06 |
| Relative Strength Index (RSI) | 28.17 |
| Average Volume (20 Days) | 19.70K |
Income Statement
In the last 12 months, Pieris Pharmaceuticals had revenue of $42.81M and earned -$24.54M in profits. Earnings per share was $-21.8.
| Revenue | 42.81M |
| Gross Profit | 1.01M |
| Operating Income | -29.76M |
| Net Income | -24.54M |
| EBITDA | -22.76M |
| EBIT | -29.76M |
| Earnings Per Share (EPS) | -21.8 |
Balance Sheet
The company has $17.40M in cash and $0 in debt, giving a net cash position of $17.40M.
| Cash & Cash Equivalents | 17.40M |
| Total Debt | 0 |
| Net Cash | 17.40M |
| Retained Earnings | -314.96M |
| Total Assets | 20.52M |
| Working Capital | 16.27M |
Cash Flow
In the last 12 months, operating cash flow was -$53.82M and capital expenditures -$171.00K, giving a free cash flow of -$53.99M.
| Operating Cash Flow | -53.82M |
| Capital Expenditures | -171.00K |
| Free Cash Flow | -53.99M |
| FCF Per Share | -47.96 |
Margins
Gross margin is 2.36%, with operating and profit margins of -69.51% and -57.33%.
| Gross Margin | 2.36% |
| Operating Margin | -69.51% |
| Pretax Margin | -57.33% |
| Profit Margin | -57.33% |
| EBITDA Margin | -53.17% |
| EBIT Margin | -69.51% |
| FCF Margin | -126.12% |
Dividends & Yields
PIRS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -164.4% |
| FCF Yield | -308.4% |
Analyst Forecast
Currently there are no analyst rating for PIRS.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Apr 23, 2024. It was a backward split with a ratio of 1:80.
| Last Split Date | Apr 23, 2024 |
| Split Type | backward |
| Split Ratio | 1:80 |
Scores
| Altman Z-Score | -21.08 |
| Piotroski F-Score | 1 |